{"id":"NCT02690714","sponsor":"Prometic Biotherapeutics, Inc.","briefTitle":"A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia","officialTitle":"A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of Prometic Plasminogen Intravenous Infusion in Subjects With Hypoplasminogenemia","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-05-04","primaryCompletion":"2017-12-17","completion":"2018-10-08","firstPosted":"2016-02-24","resultsPosted":"2021-04-19","lastUpdate":"2021-08-02"},"enrollment":15,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypoplasminogenemia","Congenital Plasminogen Deficiency"],"interventions":[{"type":"BIOLOGICAL","name":"Plasminogen (Human) intravenous","otherNames":[]}],"arms":[{"label":"6.6 mg/kg Plasminogen (Human) Intravenous","type":"EXPERIMENTAL"}],"summary":"This is a Phase 2/3 pivotal study to evaluate pharmacokinetics (PK), efficacy, and safety of Prometic Plasminogen (Human) Intravenous Lyophilized Solution, the investigational medicinal product (IMP), in pediatric and adult subjects with hypoplasminogenemia.","primaryOutcome":{"measure":"Overall Clinical Success in Number and Size of Lesions as Measured by Photographic or Other Imaging Modality Depending on the Organ System Affected or Change in Affected Organ Functionality at 48 Weeks.","timeFrame":"48 weeks","effectByArm":[{"arm":"Plasminogen (Human) Intravenous","deltaMin":34,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":2,"countries":["United States","Norway"]},"refs":{"pmids":["29321155","37674358"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":15},"commonTop":["Nasopharyngitis","Headache","Oropharyngeal pain","Diarrhoea","Cough"]}}